The growing use of insulin（胰岛素） delivery devices such as pens and pumps may help individuals with diabetes¹（糖尿病） optimize² blood glucose³（血糖） control and minimize their risk for chronic⁴ health problems associated with diabetes（糖尿病） , as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue is available free online (http://www.liebertpub.com/dia). "Improved delivery devices for insulin treatment have increased patient compliance⁵ and acceptance of an intensive insulin strategy," which can result in significant reductions in long-term complications associated with poorly controlled type 1 and type 2 diabetes, says Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, in his Editorial entitled "Impact of Insulin Delivery Devices in Diabetes Care."

The development of automated⁶ glucose-controlled insulin infusion⁷ systems that combine the advantages of continuous glucose measurement with intravenous（静脉内的） insulin infusion pumps "is likely to explode over the next several years," predicts Jay Skyler, MD, Professor of Medicine, Pediatrics, and Psychology⁸ at the University of Miami Miller⁹ School of Medicine (Florida), in the article, "Continuous Subcutaneous Insulin Infusion—An Historical Perspective."

Although insulin pump and pen technology have been available for quite some time, these devices are "underused, misused¹⁰, or poorly used," says Irl Hirsch, MD, from the University of Washington School of Medicine (Seattle). In his Concluding Remarks, "Insulin Delivery Devices—Pumps and Pens," he reviews the reasons for the poor use of diabetes technology worldwide and predicts increased adoption¹¹ of these treatment devices in the coming decade.

Eric Renard, MD, PhD, from the University of Montpellier (France), presents the factors he believes have limited insulin pump use in Europe and the need for expanded insurance coverage¹² and education to drive increased adoption of the technology. Bruce Bode¹³, MD, a diabetes specialist with Atlanta Diabetes Associates (Georgia), describes the promise and advantages insulin pumps offer for improving glucose control in type 2 diabetes, based on early-stage clinical research in this area.

Riccardo Perfetti, MD, PhD, from Sanofi-Aventis (Paris, France), explores the reasons for the marked geographical¹⁴ variation in the use of reusable and disposable insulin pens and concludes that the most important factor is likely varied¹⁵ access to the devices in different regions of the world. Perfetti also suggests that insulin pens have potential benefit for use in hospitalized patients, an application that has received too little attention.